Moliris

Moliris is a biotechnology company focused on the discovery and development of small molecule therapeutics that target RNA-binding proteins (RBPs). By leveraging a proprietary platform that integrates structural biology, machine learning, and medicinal chemistry, the company aims to unlock the therapeutic potential of RBPs, which are key regulators of gene expression. Moliris targets a variety of indications where RBP dysregulation is a primary driver, including oncology and immunological disorders. The company is headquartered in London and was founded by the life sciences venture capital firm Apple Tree Partners (ATP).